GlycoNex Announces Japanese Regulatory Submission for Denosumab Biosimilar SPD8
Regulatory decision in Japan anticipated as early as the end of 2027, subject to PMDA review; GlycoNex continues to seek partners for markets outside Japan NEW TAIPEI CITY, Nov. 8, 2026 /PRNewswire/ -- GlycoNex, Inc. (TPEx: 4168), a clinical-stage biotechnology company developing...
Covered in this story
Call it yourself
No calls on $NOV yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on NOV →Dalsna Finance is currently tracking 84 stories mentioning NOV, the earliest published 7 Oct 2025.
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.